Dio Tree

Dio Tree is an Israeli private oncology biotech developing first-in-class small molecule inhibitors of iodothyronine deiodinase type 3 (DIO3). The company is focused initially on high-grade serous ovarian cancer, where it aims to address patients who do not benefit sufficiently from standard chemotherapy, surgery, or mutation-restricted approaches such as PARP inhibitors. Its technology originated from academic inventors associated with Hadassah Medical Center and the Indian Institute of Science, and the company reports patent protection in the United States and Europe. Dio Tree positions its lead program as a novel mechanism intended for use either in combination with chemotherapy or as maintenance therapy. The broader strategy may extend to other aggressive DIO3-expressing tumors including lung, breast, colon, and pancreatic cancers.